Methods of treatment using a JAK inhibitor compound
Inventors
Kleinschek, Melanie A. • CRATER, GLENN D.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11786517-B2
Publication Date
2023-10-17
Expiration Date
Abstract
The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol or a pharmaceutically-acceptable salt thereof.
Core Innovation
The disclosed subject matter describes treatment of sarcoidosis using compound 1, identified as 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol, or a pharmaceutically acceptable salt thereof. One claim describes administering a pharmaceutical composition comprising the compound or salt and a pharmaceutically acceptable carrier to a human; another describes administering the compound or salt to a mammal. Compound 1 inhibits JAK1, JAK2, JAK3, and TYK2.
The partial content also describes treatment of respiratory diseases, including sarcoidosis, and pharmaceutical compositions with a pharmaceutically acceptable carrier. Inhalation, including use of a nebulizer inhaler, and composition or compound forms are recited among dependent-claim refinements. The background section is not included in the provided content, so the problem being solved is not explicitly described in patent.
Claims Coverage
The provided relevant claims identify two independent claims: claim 1 and claim 13. They cover treatment of sarcoidosis using the specified compound or a pharmaceutically acceptable salt, with claim 1 also requiring a pharmaceutical composition and a pharmaceutically acceptable carrier.
Treatment of sarcoidosis in a human using a pharmaceutical composition
Claim 1 covers a method of treating sarcoidosis in a human by administering a pharmaceutical composition comprising the specified compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Dependent claims further specify inhalation, a nebulizer inhaler, composition forms, and forms of the active compound.
Treatment of sarcoidosis in a mammal using the specified compound
Claim 13 covers a method of treating sarcoidosis in a mammal by administering the specified compound or a pharmaceutically acceptable salt thereof. Dependent claims further specify human subjects, inhalation, a nebulizer inhaler, and forms including the free base and crystalline hydrate.
The two independent claims cover methods of treating sarcoidosis, one using a pharmaceutical composition with a carrier in a human and the other administering the specified compound or salt to a mammal. Dependent claims refine the subject, delivery route, device, composition, and compound form.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treatment of sarcoidosis in a human or mammal using the specified compound or a pharmaceutically acceptable salt thereof.
Treatment of respiratory diseases, including sarcoidosis.
Interested in licensing this patent?